Migroben 80, 160, 320 Tablets 80 mg, 160 mg or 320 mg FC tablets
PDF Leaflet Revision Date: 07 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate essential hypertension in adults.
Dosage (summary)
80 mg or 160 mg once daily; may increase to 320 mg if needed.
Onset of Action / Duration
Onset: 2 weeks, Duration: Maximal effect at 4 weeks
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; discontinue if pregnancy occurs. Unknown if excreted in breast milk.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
- Aliskiren in Type 2 diabetes
Contraindications
- Hypersensitivity to valsartan
- History of angioedema
- Severe renal impairment
- Bilateral renal artery stenosis
- Aortic and mitral valve stenosis
Common side effects
- Fatigue
- Cough
- Abdominal pain
- Vertigo
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Discontinue if pregnancy is confirmed
Serious warnings
- Risk of hypotension in volume-depleted patients
- Angioedema risk
- Caution in renal artery stenosis
Important Disclaimer
The Migroben 80, 160, 320 Tablets 80 mg, 160 mg or 320 mg FC tablets professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
